不同剂量地塞米松对大鼠早期骨密度及成骨细胞凋亡的影响(2)
综上所述，GCs干预短期内骨密度虽无下降，但成骨细胞凋亡随剂量增加，骨折风险增加，提示临床使用GCs治疗时应尽量使用小剂量GCs，且早期应用GCs治疗时即应防范骨质疏松及骨折的发生。
参考文献：
[1]Kok C，Sambrook PN. Secondary osteoporosis in patients with an osteoporotic fracture[J]. Best Pract Res Clin Rheumatol，2009，23(6)：769-779.
[2]Majumdar SR，Morin SN，Lix LM，et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures：population-based cohort study[J]. Osteoporosis International，2013，24(9)：2493-2498.
[3]Kanis JA，Johansson H，Oden A，et al. A family history of fracture and fracture risk：a meta-analysis[J]. Bone，2004，35(5)：1029-1037.
[4]Trijau S，de Lamotte G，Pradel V，et al. Osteoporosis prevention among chronic glucocorticoid users：results from a public health insurance database[J]. RMD Open，2016，2(2)：e000249.
[5]Kan SL，Yuan ZF，Li Y，et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases：A meta-analysis[J]. Medicine(Baltimore)，2016，95(25)：e3990.
[6]Rossini M，Viapiana O，Vitiello M，et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases：the Glucocorticoid Induced OsTeoporosis TOol(GIOTTO)study[J]. Reumatismo，2017，69(1)：30.
[7]Briot K，Roux C. Glucocorticoid-induced osteoporosis[J]. RMD Open，2015，1(1)：e000014.
作者簡介：吴丽婷(1991-11)，女，汉族，广西 内分泌科，硕士研究生，研究方向：骨质疏松, 百拇医药(吴丽婷 蔡劲薇 潘吉铭 伍龙果 梁敏)
参考文献：
[1]Kok C，Sambrook PN. Secondary osteoporosis in patients with an osteoporotic fracture[J]. Best Pract Res Clin Rheumatol，2009，23(6)：769-779.
[2]Majumdar SR，Morin SN，Lix LM，et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures：population-based cohort study[J]. Osteoporosis International，2013，24(9)：2493-2498.
[3]Kanis JA，Johansson H，Oden A，et al. A family history of fracture and fracture risk：a meta-analysis[J]. Bone，2004，35(5)：1029-1037.
[4]Trijau S，de Lamotte G，Pradel V，et al. Osteoporosis prevention among chronic glucocorticoid users：results from a public health insurance database[J]. RMD Open，2016，2(2)：e000249.
[5]Kan SL，Yuan ZF，Li Y，et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases：A meta-analysis[J]. Medicine(Baltimore)，2016，95(25)：e3990.
[6]Rossini M，Viapiana O，Vitiello M，et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases：the Glucocorticoid Induced OsTeoporosis TOol(GIOTTO)study[J]. Reumatismo，2017，69(1)：30.
[7]Briot K，Roux C. Glucocorticoid-induced osteoporosis[J]. RMD Open，2015，1(1)：e000014.
作者簡介：吴丽婷(1991-11)，女，汉族，广西 内分泌科，硕士研究生，研究方向：骨质疏松, 百拇医药(吴丽婷 蔡劲薇 潘吉铭 伍龙果 梁敏)